Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection

Frontiers in Microbiology

Volumn 5, Issue DEC, 2014, Pages

  Hodgson, Susanne H ^a   Juma, Elizabeth ^b,c   Salim, Amina ^b   Magiri, Charles ^b   Kimani, Domtila ^b   Njenga, Daniel ^b   Muia, Alfred ^b   Cole, Andrew O ^b,c   Ogwang, Caroline ^b   Awuondo, Ken ^b   Lowe, Brett ^b   Munene, Marianne ^b   Billingsley, Peter F ^d   James, Eric R ^d   Gunasekera, Anusha ^d   Sim, B Kim L ^d   Njuguna, Patricia ^b   Rampling, Thomas W ^a   Richman, Adam ^d   Abebe, Yonas ^d   Kamuyu, Gathoni ^b   Muthui, Michelle ^b   Elias, Sean C ^a   Molyneux, Sassy ^b   Gerry, Stephen ^e   Macharia, Alex ^b   Williams, Thomas N ^b,f   Bull, Peter C ^b   Hill, Adrian V S ^a   Osier, Faith H ^b   Draper, Simon J ^a   Bejon, Philip ^b   Hoffman, Stephen L ^d   Ogutu, Bernhards ^b,c   Marsh, Kevin ^b   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c STRATHMORE UNIVERSITY   (Kenya)

^d SANARIA INC   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Challenge; CHMI; Falciparum; Immunity; Malaria

Indexed keywords

ANTIBODY; ANTIMEROZOITE SURFACE PROTEIN 2 ANTIBODY; ANTISCHIZONT ANTIBODY; ARTEMETHER PLUS BENFLUMETOL; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADULT; ANTIMALARIAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTOPENIA; MALARIA; MALE; NONHUMAN; PARASITE GROWTH DYNAMICS; PARASITE MULTIPLICATION RATE; PARASITE PHENOMENA AND FUNCTION; PILOT STUDY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SPOROZOITE; SYMPTOM ASSESSMENT;

PLASMODIUM FALCIPARUM;

EID: 84920682550     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00686     Document Type: Article

References (38)

1. Allison, A. C. (1954). Protection afforded by sickle-cell trait against subtertian malareal infection. Br. Med. J. 1, 290-294. doi: 10.1136/bmj.1.4857.290
2. Bray, R. S., Gunders, A. E., Burgess, R. W., Freeman, J. B., Etzel, E., Guttuso, C., et al. (1962). The inoculation of semi-immune Africans with sporozoites of Laverania falcipara (Plasmodium falciparum) in Liberia. Riv. Malariol. 41, 199-210.
3. Bruce-Chwatt, L. J. (1963a). A longitudinal longitudinal survey of natural malaria infection in a group of West African adults. I. West Afr. Med. J. 12, 141-173.
4. Bruce-Chwatt, L. J. (1963b). A longitudinal survey of natural malaria infection in a group of West African adults. West Afr. Med. J. 12, 199-217.
5. Chulay, J. D., Schneider, I., Cosgriff, T. M., Hoffman, S. L., Ballou, W. R., Quakyi, I. A., et al. (1986). Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am. J. Trop. Med. Hyg. 35, 66-68.
6. Douglas, A. D., Andrews, L., Draper, S. J., Bojang, K., Milligan, P., Gilbert, S. C., et al. (2011). Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J. Infect. Dis. 203, 1337-1340. doi: 10.1093/infdis/jir033
7. Douglas, A. D., Edwards, N. J., Duncan, C. J., Thompson, F. M., Sheehy, S. H., O'hara, G. A., et al. (2013). Comparison of modeling methods to determine liver-to-blood Inocula and parasite multiplication rates during controlled human malaria infection. J. Infect. Dis. 208, 340-345. doi: 10.1093/infdis/jit156
8. Drakeley, C. J., Corran, P. H., Coleman, P. G., Tongren, J. E., Mcdonald, S. L., Carneiro, I., et al. (2005). Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc. Natl. Acad. Sci. U.S.A. 102, 5108-5113. doi: 10.1073/pnas.0408725102
9. Duncan, C. J., Hill, A. V., and Ellis, R. D. (2012). Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum. Vaccin. Immunother. 8, 706-714. doi: 10.4161/hv.19712
10. Epstein, J. E., Rao, S., Williams, F., Freilich, D., Luke, T., Sedegah, M., et al. (2007). Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J. Infect. Dis. 196, 145-154. doi: 10.1086/518510
11. Hill, D. L., Eriksson, E. M., Carmagnac, A. B., Wilson, D. W., Cowman, A. F., Hansen, D. S., et al. (2012). Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS ONE 7:e51692. doi: 10.1371/journal.pone.0051692
12. Imoukhuede, E. B., Andrews, L., Milligan, P., Berthoud, T., Bojang, K., Nwakanma, D., et al. (2007). Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am. J. Trop. Med. Hyg. 76, 486-493.
13. Joos, C., Marrama, L., Polson, H. E., Corre, S., Diatta, A. M., Diouf, B., et al. (2010). Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS ONE 5:e9871. doi: 10.1371/journal.pone.0009871
14. Langhorne, J., Ndungu, F. M., Sponaas, A. M., and Marsh, K. (2008). Immunity to malaria: more questions than answers. Nat. Immunol. 9, 725-732. doi: 10.1038/ni.f.205
15. Liljander, A., Wiklund, L., Falk, N., Kweku, M., Martensson, A., Felger, I., et al. (2009). Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar. J. 8:78. doi: 10.1186/1475-2875-8-78
16. Marsh, K., Otoo, L., Hayes, R. J., Carson, D. C., and Greenwood, B. M. (1989). Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans. R. Soc. Trop. Med. Hyg. 83, 293-303. doi: 10.1016/0035-9203(89)90478-1
17. Mccallum, F. J., Persson, K. E., Mugyenyi, C. K., Fowkes, F. J., Simpson, J. A., Richards, J. S., et al. (2008). Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS ONE 3:e3571. doi: 10.1371/journal.pone.0003571
18. Mccarthy, J. S., Sekuloski, S., Griffin, P. M., Elliott, S., Douglas, N., Peatey, C., et al. (2011). A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS ONE 6:e21914. doi: 10.1371/journal.pone.0021914
19. Murphy, S. C., Prentice, J. L., Williamson, K., Wallis, C. K., Fang, F. C., Fried, M., et al. (2012). Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am. J. Trop. Med. Hyg. 86, 383-394. doi: 10.4269/ajtmh.2012.10-0658
20. Nieman, A. E., De Mast, Q., Roestenberg, M., Wiersma, J., Pop, G., Stalenhoef, A., et al. (2009). Cardiac complication after experimental human malaria infection: a case report. Malar. J. 8:277. doi: 10.1186/1475-2875-8-277
21. Osier, F. H., Fegan, G., Polley, S. D., Murungi, L., Verra, F., Tetteh, K. K., et al. (2008). Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect. Immun. 76, 2240-2248. doi: 10.1128/IAI.01585-07
22. Peters, J., Fowler, E., Gatton, M., Chen, N., Saul, A., and Cheng, Q. (2002). High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers. Proc. Natl. Acad. Sci. U.S.A. 99, 10689-10694. doi: 10.1073/pnas.162349899
23. Polley, S. D., Conway, D. J., Cavanagh, D. R., Mcbride, J. S., Lowe, B. S., Williams, T. N., et al. (2006). High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 24, 4233-4246. doi: 10.1016/j.vaccine.2005.06.030
24. Roestenberg, M., Bijker, E. M., Sim, B. K., Billingsley, P. F., James, E. R., Bastiaens, G. J., et al. (2013). Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 88, 5-13. doi: 10.4269/ajtmh.2012.12-0613
25. Roestenberg, M., De Vlas, S. J., Nieman, A. E., Sauerwein, R. W., and Hermsen, C. C. (2012a). Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. J. Infect. Dis. 206, 319-323. doi: 10.1093/infdis/jis355
26. Roestenberg, M., O'hara, G. A., Duncan, C. J., Epstein, J. E., Edwards, N. J., Scholzen, A., et al. (2012b). Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS ONE 7:e38434. doi: 10.1371/journal.pone.0038434
27. Sauerwein, R. W., Roestenberg, M., and Moorthy, V. S. (2011). Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat. Rev. Immunol. 11, 57-64. doi: 10.1038/nri2902
28. Sheehy, S. H., Douglas, A. D., and Draper, S. J. (2013a). Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum. Vaccin. Immunother. 9, 1831-1840. doi: 10.4161/hv.25383
29. Sheehy, S. H., Duncan, C. J., Elias, S. C., Choudhary, P., Biswas, S., Halstead, F. D., et al. (2012). ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20, 2355-2368. doi: 10.1038/mt.2012.223
30. Sheehy, S. H., Spencer, A. J., Douglas, A. D., Sim, B. K., Longley, R. J., Edwards, N. J., et al. (2013b). Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS ONE 8:e65960. doi: 10.1371/journal.pone.0065960
31. Shekalaghe, S., Rutaihwa, M., Billingsley, P. F., Chemba, M., Daubenberger, C. A., James, E., et al. (2014). Controlled human malaria infection of tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 91, 471-480. doi: 10.4269/ajtmh.14-0119
32. Spring, M. D., Cummings, J. F., Ockenhouse, C. F., Dutta, S., Reidler, R., Angov, E., et al. (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4:e5254. doi: 10.1371/journal.pone.0005254
33. Thompson, F. M., Porter, D. W., Okitsu, S. L., Westerfeld, N., Vogel, D., Todryk, S., et al. (2008). Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3:e1493. doi: 10.1371/journal.pone.0001493
34. Tippett, E., Fernandes, L. A., Rogerson, S. J., and Jaworowski, A. (2007). A novel flow cytometric phagocytosis assay of malaria-infected erythrocytes. J. Immunol. Methods 325, 42-50. doi: 10.1016/j.jim.2007.05.012
35. Van Meer, M. P., Bastiaens, G. J., Boulaksil, M., De Mast, Q., Gunasekera, A., Hoffman, S. L., et al. (2014). Idiopathic acute myocarditis during treatment for controlled human malaria infection: a case report. Malar. J. 13:38. doi: 10.1186/1475-2875-13-38
36. Wampfler, R., Mwingira, F., Javati, S., Robinson, L., Betuela, I., Siba, P., et al. (2013). Strategies for detection of Plasmodium species gametocytes. PLoS ONE 8:e76316. doi: 10.1371/journal.pone.0076316
37. Warimwe, G. M., Keane, T. M., Fegan, G., Musyoki, J. N., Newton, C. R., Pain, A., et al. (2009). Plasmodium falciparum var gene expression is modified by host immunity. Proc. Natl. Acad. Sci. U.S.A. 106, 21801-21806. doi: 10.1073/pnas.0907590106
38. White, N. J., Pukrittayakamee, S., Hien, T. T., Faiz, M. A., Mokuolu, O. A., and Dondorp, A. M. (2014). Malaria. Lancet 383, 723-735. doi: 10.1016/S0140-6736(13)60024-0